TherapeuticsMD, Inc. (NASDAQ:TXMD) saw a large increase in short interest during the month of December. As of December 29th, there was short interest totalling 55,882,896 shares, an increase of 4.4% from the December 15th total of 53,505,064 shares. Currently, 32.1% of the company’s shares are short sold. Based on an average trading volume of 2,720,761 shares, the days-to-cover ratio is presently 20.5 days.
Shares of TherapeuticsMD (NASDAQ TXMD) opened at $6.15 on Monday. The stock has a market cap of $1,330.00, a P/E ratio of -15.77 and a beta of 1.06. TherapeuticsMD has a 1 year low of $3.50 and a 1 year high of $8.30.
TherapeuticsMD (NASDAQ:TXMD) last posted its earnings results on Monday, November 6th. The company reported ($0.07) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.10) by $0.03. TherapeuticsMD had a negative net margin of 457.00% and a negative return on equity of 65.16%. The firm had revenue of $4.42 million during the quarter, compared to the consensus estimate of $5.36 million. During the same quarter in the prior year, the company earned ($0.13) EPS. The company’s revenue was down 19.7% on a year-over-year basis. research analysts anticipate that TherapeuticsMD will post -0.37 earnings per share for the current year.
In related news, Director Tommy G. Thompson acquired 5,000 shares of the company’s stock in a transaction dated Friday, December 8th. The stock was bought at an average price of $6.21 per share, with a total value of $31,050.00. Following the purchase, the director now directly owns 3,555 shares in the company, valued at approximately $22,076.55. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Corporate insiders own 23.92% of the company’s stock.
Large investors have recently modified their holdings of the business. Amalgamated Bank grew its position in TherapeuticsMD by 7.2% in the second quarter. Amalgamated Bank now owns 19,744 shares of the company’s stock valued at $104,000 after acquiring an additional 1,322 shares in the last quarter. Principal Financial Group Inc. grew its position in TherapeuticsMD by 3.9% in the second quarter. Principal Financial Group Inc. now owns 21,711 shares of the company’s stock valued at $114,000 after acquiring an additional 818 shares in the last quarter. Virtu KCG Holdings LLC acquired a new stake in TherapeuticsMD in the second quarter valued at approximately $157,000. Quantbot Technologies LP acquired a new stake in TherapeuticsMD in the third quarter valued at approximately $189,000. Finally, Cetera Investment Advisers acquired a new stake in TherapeuticsMD in the second quarter valued at approximately $214,000. 73.69% of the stock is owned by institutional investors.
TherapeuticsMD Company Profile
TherapeuticsMD, Inc is a women’s healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials are designed to alleviate symptoms of and reduce health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort.
Receive News & Ratings for TherapeuticsMD Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TherapeuticsMD and related companies with MarketBeat.com's FREE daily email newsletter.